4.5 Article

Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients A potential role for G-CSF

期刊

CANCER BIOLOGY & THERAPY
卷 9, 期 9, 页码 743-748

出版社

TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.9.9.11551

关键词

endothelial cells; G-CSF; angiogenesis pathologic; cytokines; growth factors; liver surgery

类别

资金

  1. University Medical Center of Utrecht, department Medical Oncology and department Surgical Oncology

向作者/读者索取更多资源

Background: In preclinical models recruitment of bone-marrow derived (endothelial) progenitor cells (BD(E)PCs) contributes to tumor growth and metastasis formation. Here we investigated whether these (E) PCs and mobilizing cytokines are released after partial hepatectomy or radiofrequency ablation (RFA) for liver tumors. In addition, we tested whether G-CSF could play a role in EPC mobilization in mice and in human volunteers. Results: Patients undergoing partial hepatectomy or RFA showed an instantaneous release of EPCs following laparotomy and mobilization of the liver. Elevated EPC levels were maintained during the entire procedure, but dropped to near-baseline levels 4 h after completion of the procedure. Plasma G-CSF levels showed a 5-10-fold increase after the procedure and low-dose G-CSF administration to mice or healthy volunteers was sufficient to induce an immediate release of EPCs. Surgery also caused an increase in the plasma levels of VEGF, but not SDF-1 alpha. Methods: Before, during and after liver surgery plasma and mononuclear cells were collected from 12 patients undergoing partial hepatectomy or RFA. To explore the role of G-CSF C57Bl/6 mice and 20 human volunteers received G-CSF (0.3, 3 or 300 mu g). In all individuals, (E) PC numbers were determined by flow cytometry at predefined timepoints shortly after therapy. Plasma levels of G-CSF, VEGF and SDF-1 alpha were measured by ELISA. Conclusion: Compliant with previous published data concerning VDA and chemotherapy treatment, liver surgery induces an instantaneous release of EP Cs, conceivably in response to elevated G-CSF levels. This suggests the value of exploring therapeutic avenues to prevent this process.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome

Johanna A. A. Bult, Jessica R. Placa, Erlin A. Haacke, M. Martijn Terpstra, Gwenny M. Verstappen, Frederik K. L. Spijkervet, Frans G. M. Kroese, Wouter J. Plattel, Joost S. P. Vermaat, Hendrika Bootsma, Bert van der Vegt, Arjan Diepstra, Anke van den Berg, Klaas Kok, Marcel Nijland

Summary: This study investigated the genomic characteristics of parotid gland-associated mucosa-associated lymphoid tissue (MALT) extranodal marginal zone lymphoma (ENMZL) in primary Sjogren's syndrome (pSS). The findings showed that pSS-associated MALT lymphomas have a low mutational load and limited copy number alterations, suggesting that they are genomically stable and may depend on a stimulatory micro-environment.

CANCERS (2022)

Article Hematology

Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study

Mirian Brink, Frederik O. Meeuwes, Marjolein W. M. van der Poel, Marie Jose Kersten, Marielle Wondergem, Pim G. N. J. Mutsaers, Lara H. Bohmer, F. J. Sherida H. Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M. Jansen, Wouter Plattel, Gerwin A. Huls, Joost S. P. Vermaat, Marcel Nijland

Summary: In patients aged <65 years with PTCL, the addition of etoposide and consolidation with ASCT improved overall survival rates, particularly in ALK(+) ALCL patients. ASCT consolidation was associated with improved survival rates in patients with ALCL, AITL, or PTCL, while the addition of etoposide did not show significant correlation with survival rates.
Review Oncology

Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach

Fleur A. de Groot, Ruben A. L. de Groen, Anke van den Berg, Patty M. Jansen, King H. Lam, Pim G. N. J. Mutsaers, Carel J. M. van Noesel, Martine E. D. Chamuleau, Wendy B. C. Stevens, Jessica R. Placa, Rogier Mous, Marie Jose Kersten, Marjolein M. W. van der Poel, Thomas Tousseyn, F. J. Sherida H. Woei-a-Jin, Arjan Diepstra, Marcel Nijland, Joost S. P. Vermaat

Summary: This review summarizes the insights from gene-expression profiling studies on the background and origination of diffuse large B-cell lymphomas (DLBCL). By combining transcriptomics with genomics, proteomics, and patient characteristics, diagnostic classification, prognostication, and the development of new targeted therapeutic strategies in DLBCL can be improved.

CANCERS (2022)

Meeting Abstract Oncology

METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors

S. Postel-Vinay, A. Italiano, P. Martin Romano, P. A. Cassier, L. L. Siu, I. S. Lossos, J. F. Hilton, M. A. Mckean, J. Strauss, G. S. Falchook, M. J. A. de Jonge, F. L. Opdam, D. Rasco, J. S. Vermaat, T. Crossman, M. Zajac, A. Hainline, B. Kremer, O. Barbash, M. M. Gounder

ANNALS OF ONCOLOGY (2022)

Article Oncology

Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis

Frederik O. Meeuwes, Mirian Brink, Marjolein W. M. Van Der Poel, Marie Jose Kersten, Marielle Wondergem, Pim G. N. J. Mutsaers, Lara Bohmer, Sherida Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M. Jansen, Arjan Diepstra, Tjeerd J. F. Snijders, Wouter J. Plattel, Gerwin A. Huls, Joost S. P. Vermaat, Marcel Nijland

Summary: Although rituximab improved overall response rate (ORR) for patients with AITL, there was no significant impact on progression-free survival (PFS) and overall survival (OS).

EUROPEAN JOURNAL OF CANCER (2022)

Article Multidisciplinary Sciences

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity

Ziva Pogacar, Jackie L. Johnson, Lenno Krenning, Giulia De Conti, Fleur Jochems, Cor Lieftink, Arno Velds, Leyma Wardak, Kelvin Groot, Arnout Schepers, Liqin Wang, Ji-Ying Song, Marieke van de Ven, Olaf van Tellingen, Rene H. Medema, Roderick L. Beijersbergen, Rene Bernards, Rodrigo Leite de Oliveira

Summary: This study found that the use of the CDK2 inhibitor, indisulam, can enhance the induction of senescence in cancer cells by the CDK4/6 inhibitor, palbociclib, and sensitize the cells to senolytic therapy.

PLOS ONE (2022)

Editorial Material Oncology

UNCAN.eu, a European Initiative to UNderstand CANcer

Eric Solary, Patricia Blanc, Michael Boutros, Charis Girvalaki, Franco Locatelli, Rene H. Medema, Peter Nagy, Josep Tabernero

Summary: UNCAN.eu is a European initiative aimed at advancing cancer research through the creation of a research data hub, leading to new developments in cancer care.

CANCER DISCOVERY (2022)

Correction Oncology

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site (vol 124, pg 777, 2021)

Maud Kamal, Sonia Lameiras, Marc Deloger, Adeline Morel, Sophie Vacher, Charlotte Lecerf, Celia Dupain, Emmanuelle Jeannot, Elodie Girard, Sylvain Baulande, Coraline Dubot, Gemma Kenter, Ekaterina Jordanova, Els M. J. J. Berns, Guillaume Bataillon, Marina Popovic, Roman Rouzier, Wulfran Cacheux, Christophe Le Tourneau, Alain Nicolas, Nicolas Servant, Suzy Scholl, Ivan Bieche, RAIDs Consortium

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity

Claire Vennin, Chiara M. Cattaneo, Leontien Bosch, Serena Vegna, Xuhui Ma, Hugo G. J. Damstra, Moreno Martinovic, Efi Tsouri, Mila Ilic, Leyla Azarang, Jan R. T. van Weering, Emilia Pulver, Amber L. Zeeman, Tim Schelfhorst, Jeroen O. Lohuis, Anne C. Rios, Johanna F. Dekkers, Leila Akkari, Renee Menezes, Rene Medema, Serena R. Baglio, Anna Akhmanova, Sabine C. Linn, Simone Lemeer, Dirk M. Pegtel, Emile E. Voest, Jacco van Rheenen

Summary: Although treatment with taxanes may not always be effective, it carries the risk of side effects like peripheral neuropathy. A study found that taxanes can directly stimulate T cells to selectively kill cancer cells, independent of the T cell receptor. This mechanism involves the release of cytotoxic extracellular vesicles by T cells, inducing apoptosis specifically in tumor cells. These findings were utilized to develop a therapeutic approach using pre-treated T cells, avoiding systemic toxicity.

CANCER CELL (2023)

Article Oncology

MND1 enables homologous recombination in somatic cells primarily outside the context of replication

Lisa Koob, Anoek Friskes, Louise van Bergen, Femke M. Feringa, Bram van den Broek, Emma S. Koeleman, Ellis van Beek, Michael Schubert, Vincent A. Blomen, Thijn R. Brummelkamp, Lenno Krenning, Rene H. Medema

Summary: This study demonstrates that the meiotic recombination co-factor MND1 plays a role in the repair of DNA double-strand breaks (DSBs) in somatic cells. MND1 localizes to DSBs and stimulates DNA repair through homologous recombination (HR). Importantly, MND1 specifically functions in the repair response to two-ended DSBs induced by irradiation (IR) or chemotherapeutic drugs, and its activity is primarily observed in the G2 phase.

MOLECULAR ONCOLOGY (2023)

Article Oncology

A non-randomized risk-adjusted comparison of lenalidomide plus R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

A. Vera de Jonge, Erik van Werkhoven, Avinash G. Dinmohamed, Marcel Nijland, Aeilko H. Zwinderman, Patrick M. Bossuyt, Martine S. Veldhuis, Emma G. G. M. Rutten, Rogier Mous, Joost S. P. Vermaat, Yorick Sandberg, Eva de Jongh, Yavuz M. Bilgin, Rinske Boersma, Harry Koene, Marie Jose Kersten, Daphne de Jong, Martine E. D. Chamuleau

Summary: In a study conducted in the Netherlands, researchers found that R2CHOP treatment significantly improved the prognosis of DLBCL patients compared to R-CHOP treatment, based on a non-randomized risk-adjusted comparison.

BLOOD CANCER JOURNAL (2023)

Article Oncology

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics

Johanna A. A. Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Joost Kluiver, Sanne H. Tonino, Joost S. P. Vermaat, Martine E. D. Chamuleau, Arjan Diepstra, Anke van den Berg, Wouter J. Plattel, Mirian Brink, Marcel Nijland

Summary: This population-based study reveals the clinical characteristics associated with transformation and survival after transformation of marginal zone lymphoma (tMZL). Elevated LDH and nodal MZL subtype at MZL diagnosis increase the risk of transformation, while radiotherapy reduces the risk. Age >60 years and (immuno)chemotherapy before transformation are associated with an increased risk of relapse and mortality. Two-year progression-free survival and overall survival are higher for R-(mini)CHOP-treated tMZL patients.

BLOOD CANCER JOURNAL (2023)

Article Cell Biology

Perturbations in 3D genome organization can promote acquired drug resistance

Anna G. Manjon, Stefano Giustino Manzo, Stefan Prekovic, Leon Potgeter, Tom van Schaik, Ning Qing Liu, Koen Flach, Daniel Peric-Hupkes, Stacey Joosten, Hans Teunissen, Anoek Friskes, Mila Ilic, Dorine Hintzen, Vinicius H. Franceschini-Santos, Wilbert Zwart, Elzo de Wit, Bas van Steensel, Rene H. Medema

Summary: Acquired drug resistance is a major problem in cancer treatment. The study reveals that dissociation of the nuclear lamina can lead to derepression of the ABCB1 gene, resulting in drug resistance. This finding suggests that disruption of 3D genome topology plays an important role in tumor evolution and the acquisition of drug resistance.

CELL REPORTS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer

Esther Strating, Anne van de Loo, Sjoerd Elias, Marnix Lam, Onno Kranenburg

PET CLINICS (2023)

Article Oncology

Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities

Janneke W. de Boer, Kylie Keijzer, Elise R. A. Pennings, Jaap A. van Doesum, Anne M. Spanjaart, Margot Jak, Pim G. N. J. Mutsaers, Suzanne van Dorp, Joost S. P. Vermaat, Marjolein W. M. van der Poel, Lisanne V. van Dijk, Marie Jose Kersten, Anne G. H. Niezink, Tom van Meerten, Dutch CAR-T Tumorboard Consortium

Summary: CAR-T cell therapy has become the standard treatment for patients with relapsed or refractory large B-cell lymphoma. However, it can be accompanied by toxicities. It is important to identify patients at risk for these toxicities in order to start early intervention. Existing risk scores for predicting these toxicities have limitations and require further validation and optimization.

CANCERS (2023)

暂无数据